UChicago Medicine hopes to expand its cancer care nationwide, announces first affiliation with Kansas hospital
UChicago Medicine announced its first affiliation Tuesday with AdventHealth Cancer Institute Shawnee Mission in the Kansas City area. As part of the affiliation, patients at the Kansas cancer institute will have access to UChicago Medicine treatments, clinical trials and second opinions from UChicago Medicine doctors.
The Kansas cancer institute will remain an independent entity but align with UChicago Medicine when it comes to standards in clinical care, medical education and research. A UChicago Medicine spokesperson did not answer questions about the financial details of the arrangement.
The UChicago Medicine Cancer Network is "uniquely positioned to provide expertise nationwide," said Dr. Kunle Odunsi, director of the UChicago Medicine Comprehensive Cancer Center.
U.S. News & World Report ranks University of Chicago Medical Center as the 12th best hospital for cancer in the country and the best hospital for cancer in the Chicago area.
"The goal is to take these types of opportunities to communities where patients live so that a patient in Kansas does not have to travel to Chicago to receive UChicago Cancer Center type of care," Odunsi said. "They can remain in their local area and have incredible access just like anyone who lives in our region."
Dr. Brenda Shoup, medical director of AdventHealth Cancer Institute, said in a news release, "We're bringing nationally recognized expertise and innovation to our community - ensuring our patients have access to the latest treatments and research without having to travel far."
It could be the first of a number of affiliations for the UChicago Medicine Cancer Network.
UChicago Medicine is beginning discussions with other health systems about additional affiliations, Odunsi said.
"We continue to invest (locally) but we believe that we have a lot to offer beyond our local region, a lot to offer across the country, so there is no specific number right now (of possible affiliations) but where the opportunities arise we will take advantage of those opportunities," Odunsi said.
UChicago Medicine joins a growing trend, as it works to collaborate with health systems across the country for cancer care.
Rush University System for Health partnered with University of Texas MD Anderson Cancer Center last year. U.S. News & World Report ranks MD Anderson Cancer Center as the No. 1 cancer hospital in the country.
Related Articles
• Mokena fundraiser offers connections for people with neuromuscular disease
• Walmart recalls frozen shrimp over potential radioactive contamination
• US pediatricians' new COVID-19 shot recommendations differ from CDC advice
• Abbott Laboratories scores a win in federal court, as it faces hundreds of suits over formula for preterm babies
• ICE spared him from deportation to Venezuela. He donated a kidney to save his ailing brother in the Chicago area.
Under that partnership, the Rush Cancer Center was renamed as the Rush MD Anderson Cancer Center. Rush said, when the partnership was announced, it would allow protocols and cancer treatment plans at Rush to mirror those available at MD Anderson, give patients access to more clinical trials, and allow Rush doctors to consult with MD Anderson doctors on treatment decisions.
Rush is one of seven health systems across the country that have partnered with the MD Anderson Cancer Network.
Northwestern Medicine also, in the past year, announced collaborations with multiple Florida health systems.
In June, Northwestern announced a collaboration with Florida's BayCare that would give BayCare access to more medical treatments, clinical research and training opportunities for current and future physicians in west central Florida.
Last fall, Northwestern said it would collaborate with Florida's Naples Comprehensive Health, allowing Naples' to take advantage of Northwestern's clinical trials, oncology experts and offer its patients second opinions from Northwestern doctors.
Health systems are increasingly focusing on cancer care, with demand climbing as baby boomers age. The Centers for Disease Control & Prevention has projected a 49% increase in annual cancer cases between 2015 and 2050.
Chicago-area hospitals have been working to expand and improve their cancer offerings locally as well.
UChicago Medicine is building a 575,000-square-foot freestanding cancer hospital on Chicago's South Side. Scheduled to open in 2027, that cancer center is intended to give South Side residents greater access to cancer care while attracting patients from across the region.
Northwestern is also hoping to build a new tower on its Streeterville campus with more than 200 beds that would also consolidate oncology services now spread across five buildings on the hospital campus.
Endeavor Health is adding a two-story addition to its Knowles Cancer Center at Endeavor Health Elmhurst Hospital, and converting a floor of the Galter Medical Pavillion at Endeavor Health Swedish Hospital into a cancer space with additional rooms.
UChicago Medicine previously acquired a controlling interest in four AdventHealth hospitals in west suburban Bolingbrook, Glendale Heights, Hinsdale and La Grange. That deal, however, involved only AdventHealth's Great Lakes Region. AdventHealth has hospitals and care sites across nine states.
Copyright (C) 2025, Tribune Content Agency, LLC. Portions copyrighted by the respective providers.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Chicago Tribune
28 minutes ago
- Chicago Tribune
Doctors: 2025 will be the year of measles in North America. Why?
Looking back, 2025 may be characterized as 'the year of measles in North America.' The U.S. has recorded its highest number of measles cases in more than 30 years, although cases have tailed off significantly in the last eight weeks and are only slightly higher than they were in 2019. The current per capita incidence of measles in the U.S. is roughly 4 per 1 million people. While there is a cyclical component to measles every several years, declining vaccination rates are by far the largest factor in this increase. According to Johns Hopkins University, the average county-level vaccination rate in the U.S. for measles, mumps and rubella declined from 93.9% pre-pandemic to 91.3% post-pandemic, moving further away from the 95% herd immunity threshold necessary to limit the spread of measles. (There are actually far more people vaccinated in the U.S. than there were in 2000, when measles was 'eliminated' but the U.S. population has risen by 20% since then, and the number of unvaccinated has outpaced the population rise.) This is simply the latest illustration of the importance of vaccines. Even small decreases in vaccination rates can have big consequences. Which brings us to Health and Human Services Secretary Robert F. Kennedy Jr. and his fraught relationship with the mRNA vaccine, the unique delivery system that carries genetic material into the body's cells to create an immune response against viral proteins. Under Kennedy's guidance, HHS will gradually wind down its mRNA vaccine development programs and cancel 22 vaccine projects that have funding totaling $500 million. Some mRNA contracts in their final stages will be allowed to conclude, but no new mRNA projects will be put in place. The government is essentially getting out of the mRNA business. During the COVID-19 pandemic, Operation Warp Speed, the federal initiative to rapidly develop an mRNA vaccine for the coronavirus, saved thousands of lives in the U.S. and millions of lives worldwide. The immune response created by the vaccine conferred relative protection for those infected and the severity of COVID-19 infections gradually declined. Besides this, those vaccinated with the mRNA vaccine were at less risk of developing post-COVID-19 persistent fatigue and other physical problems, known as long COVID. Recent data from a national study led by Rush University in Chicago found that those who did develop long COVID returned to full employment with fewer financial hardships if they had been vaccinated. Not that the mRNA-powered COVID-19 vaccine was perfect. It decreased disease severity but did not prevent infection or transmission. The immunity it confers is short-lived, so patients must be revaccinated at frequent intervals. Side effects are rare, but heart inflammation in young men is not uncommon. Kennedy's oft-intemperate and sometimes-unscientific remarks about vaccines have generated fierce criticism from the public health community and much of the mainstream press. His critics have made equally intemperate remarks, suggesting that Kennedy will have the blood of millions on his hands. Not yet anyway, but it makes it difficult to analyze in sober fashion what Kennedy is doing. What he is doing is rolling the dice. The strength of mRNA technology was that it could be developed and modified quickly in comparison to other non-mRNA vaccine technologies (almost nobody expected the mRNA COVID-19 vaccine to be ready as soon as it was). Scrapping mRNA research means the country might be unprepared upon the arrival of the next pandemic — whether it is a new COVID-19 strain, bird flu or some other agent that requires a rapid response. Kennedy and his HHS minions are redirecting efforts toward what they hope are improved technologies. He seeks vaccines developed with more transparency that are safer and more durable and can address the shortcomings of mRNA vaccines. Maybe that will happen. Currently, other platforms include inactivated vaccines that use the actual organism to stimulate the immune system (flu vaccine); attenuated vaccines that use a weakened form of the organism to cause a mild infection (measles vaccine); and conjugate vaccines that use parts of the organism that don't cause infection but train the immune system to respond (meningitis vaccine). But developing and testing new platforms takes time, and the vaccines created may still underperform in real-world usage. Is Kennedy's move to abandon mRNA research a calculated risk or a rash one? No one — not experts, the media nor the public — can say with confidence because the future and the science are uncertain. The next pandemic may occur in a year, a decade or a generation. Answering that question will require patience, intellectual honesty, humility and wisdom. The Kennedy family has always walked the fine line between fantastic luck and accomplishment on one side and tragic misfortune on the other. Let's hope the Kennedy luck is with the country here. Dr. Cory Franklin is a retired intensive care physician and the author of 'The COVID Diaries 2020-2024: Anatomy of a Contagion as it Happened.' Dr. Robert Weinstein is an infectious disease specialist at Rush University Medical Center.
NBC News
an hour ago
- NBC News
For some, fall Covid shots may come with copays — or no coverage at all
If you're in good health and plan to get a Covid shot this fall, you might end up with an unwelcome surprise: a bill. The Food and Drug Administration is expected to approve the next round of Covid shots soon, but only for a smaller, high-risk group — adults 65 and older and people with underlying health conditions. The Centers for Disease Control and Prevention is likely to follow suit, limiting its recommendation on who should get the shots to the same groups. (The CDC currently recommends Covid vaccination for everyone 6 months and older.) The change, experts say, could affect what insurers are willing to cover for everyone else who doesn't fall under a high-risk group. By law, most health insurance plans are required to fully cover vaccines recommended by the CDC and its outside advisory committee, the Advisory Committee on Immunization Practices (ACIP). For those who don't fall under the CDC's new recommendations, experts say coverage would depend entirely on their insurance — with some deciding to fully cover the shot, others requiring a copay and some not covering it at all. Without insurance, a Covid shot can cost up to $140, according to the CDC's vaccine price list. 'It could very well get confusing,' said Dr. William Schaffner, an infectious disease expert at Vanderbilt University Medical Center in Nashville, Tennessee, and an adviser to ACIP. Whether you're able to get a free shot 'may greatly depend on which company with which you have your insurance.' Who can get a Covid vaccine? Under the expected recommendations from the CDC, healthy children and adults won't be barred from getting the Covid vaccine, said Dorit Reiss, a vaccine policy expert at UC Law San Francisco. 'It's legal to give a vaccine off-label,' Reiss said, referring to when a doctor prescribes a drug for something different than what the FDA approved it for, 'and insurance companies can choose to cover them.' A spokesperson for AHIP, a health insurance industry trade group, said that every individual insurer will come up with its own policy following the CDC's final guidance. The CDC's list of conditions that put a person at high risk for severe illness from Covid is extensive, and includes cancer, heart disease and lung conditions as well as physical inactivity and depression. Insurers also take into account clinical recommendations from outside medical organizations, like the American College of Obstetricians and Gynecologists and the American Academy of Pediatrics, the spokesperson said. On Tuesday, the AAP, which has expressed its disapproval for Health Secretary Robert F. Kennedy Jr.'s vaccine decisions, released its own recommendations supporting Covid vaccinations for children. Most people are also unlikely to notice changes to their insurance coverage overnight — if there are any, according to the AHIP spokesperson. For private plans — including Obamacare plans — any changes stemming from ACIP meetings could likely only be implemented in the next benefit year, typically Jan. 1, the spokesperson said. That means it's possible that people who get a shot before then might be covered. Medicare and Medicaid plans are required to follow ACIP recommendations immediately upon the CDC director's signature. Covid vaccines have also already been factored into insurers' plans for this year. In an emailed statement, a spokesperson for Blue Cross and Blue Shield said that 'each independent Blue Cross and Blue Shield plan will make their own coverage decisions.' Covid and flu shots The changes could affect people planning to get their Covid and flu vaccines at the same time. Schaffner, of Vanderbilt, said some people choose to get their Covid and flu shots at the same time, but there are concerns that some could be turned away due to the anticpated change in recommendations. He added that misinformation about who is able to get the Covid shots may also discourage people from getting either vaccine. 'I think we have to reassure people, particularly those at high risk, that the vaccine will be available to them,' he said. Rick Gates, Walgreens' chief pharmacy officer, said its pharmacists usually determine whether a patient has coverage before a vaccine is administered. Because of this, it's unlikely anyone would be hit with a surprise bill due to new CDC recommendations, he said, adding that the patient would first be told whether the vaccine is fully covered, a copay is required or the patient must pay entirely out of pocket. Gates said that people are already coming in for their flu shot, but many seem to be holding off on the Covid shot until the updated version is available. During last year's respiratory virus season peak, he said, more than 50% of patients got both shots at once — a number that has grown over the past two to three years.
Fox News
2 hours ago
- Fox News
Operation Warp Speed was miraculous. Trump admin should not abandon technology that made it possible
"From the instant the coronavirus invaded our shores, we raced into action to develop a safe and effective vaccine at breakneck speed… We harnessed the full power of government, the genius of American scientists, and the might of American industry to save millions and millions of lives all over the world… The gold standard vaccine has been done in less than nine months." That's not a pharmaceutical company executive, scientist or public health official talking. It's President Donald Trump. President Trump made those remarks in 2020 at a White House summit celebrating his administration's Operation Warp Speed initiative. Traditional vaccines often take years to develop. But thanks to a groundbreaking technology called mRNA and tremendous partnerships between government agencies and private companies, a powerful vaccine for COVID-19 was developed less than a year after the virus was sequenced. His prediction that those vaccines would be a game-changer turned out to be correct. COVID-19 vaccines saved at least 3.2 million lives in the United States and millions more around the world. During a very dark time, it was an incredible achievement for our country. Yet Secretary of Health and Human Services Robert F. Kennedy Jr. is undermining that achievement by canceling substantial federal research investments in mRNA – the technology that has already led to approved vaccines for COVID-19 and RSV, and holds tremendous potential for future treatments and cures for many diseases. Instead of supporting researchers on the verge of revolutionizing vaccine science and saving countless lives, Secretary Kennedy has chosen to tie their hands. This decision will slow our progress, leave our nation underprepared for the next major public health emergency, and significantly damage America's leadership in the scientific and medical fields. President Trump should direct Secretary Kennedy to immediately reverse this shortsighted decision. As a pediatrician for more than 30 years, I cared for children from all walks of life. Some had great health insurance; others had none. Some lived in wealthy neighborhoods; others grew up in poverty. But regardless of their circumstances, I strived to give every one of my patients the best possible care. That's how every doctor should approach medicine, and it's also how policymakers should approach their jobs. Health is too important to be politicized. Scientists have been studying mRNA technology for decades, and the more than 13 billion doses of COVID-19 vaccines that have been administered worldwide since 2020 have allowed researchers to assess their impact. The results are clear. mRNA technology has already saved millions of lives. It is also incredibly safe; the vast majority of side effects associated with mRNA COVID-19 vaccines are minor and do not require medical intervention. The beauty of this particular technology is that scientists can quickly update and adapt those vaccines to keep up with changes in the viruses they are targeting without sacrificing quality or safety. But the potential benefits of mRNA technology go well beyond a single virus. Scientists are working on mRNA vaccines and treatments that can target multiple types of cancer, genetic disorders, several other respiratory viruses and all kinds of rare diseases. Funding mRNA research now is also critical to helping us get ahead of the next big public health emergency, whenever and wherever it arrives. That is why Secretary Kennedy's decision to terminate federal mRNA research investments and instead rely on older and slower vaccine technology is deeply flawed. Health secretaries should not be denying Americans proven medical care. Stopping medical innovation in its tracks purely for ideological purposes is just wrong. When it comes to your health, listen to the people you trust the most – your doctor or nurse – rather than politicians. As President Trump has said, COVID-19 vaccines are a "medical miracle," and mRNA holds so much promise for more Operation Warp Speed-type victories in the years ahead. But for that to happen, politicians need to unleash American innovation and let our scientists and researchers do what they do best.
